These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33171664)

  • 21. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis.
    Kim MJ; Jones N; Steeples LR
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
    Tarsia M; Vitale A; Gaggiano C; Sota J; Maselli A; Bellantonio C; Guerriero S; Dammacco R; La Torre F; Ragab G; Hegazy MT; Fonollosa A; Paroli MP; Del Giudice E; Maggio MC; Cattalini M; Fotis L; Conti G; Mauro A; Civino A; Diomeda F; de-la-Torre A; Cifuentes-González C; Tharwat S; Hernández-Rodríguez J; Gómez-Caverzaschi V; Pelegrín L; Babu K; Gupta V; Minoia F; Ruscitti P; Costi S; Breda L; La Bella S; Conforti A; Mazzei MA; Carreño E; Amin RH; Grosso S; Frediani B; Tosi GM; Balistreri A; Cantarini L; Fabiani C
    Ophthalmol Ther; 2024 Mar; 13(3):761-774. PubMed ID: 38206518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF-alpha therapy for sight threatening uveitis.
    Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
    Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the systemic management of noninfectious uveitis in children and adolescents.
    Leal I; Steeples LR; Wong SW; Giuffrè C; Pockar S; Sharma V; Green EKY; Payne J; Jones NP; Chieng ASE; Ashworth J
    Surv Ophthalmol; 2024; 69(1):103-121. PubMed ID: 36682467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
    Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
    Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.
    Rosenbaum JT; Bodaghi B; Couto C; Zierhut M; Acharya N; Pavesio C; Tay-Kearney ML; Neri P; Douglas K; Pathai S; Song AP; Kron M; Foster CS
    Semin Arthritis Rheum; 2019 Dec; 49(3):438-445. PubMed ID: 31301816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of severe complications in Behçet's disease with TNF inhibitors.
    Desbois AC; Vallet H; Domont F; Comarmond C; Cacoub P; Saadoun D
    Expert Opin Biol Ther; 2017 Jul; 17(7):853-859. PubMed ID: 28503960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis.
    Garweg JG; Straessle KA
    Ocul Immunol Inflamm; 2024 May; ():1-8. PubMed ID: 38709218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behçet's Disease Uveitis.
    Joubert M; Desbois AC; Domont F; Ghembaza A; Le Joncour A; Mirouse A; Maalouf G; Leclercq M; Touhami S; Cacoub P; Bodaghi B; Saadoun D
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-α2a treatment for refractory Behçet's disease.
    Lai YJ; Chan WC
    Taiwan J Ophthalmol; 2018; 8(3):168-172. PubMed ID: 30294531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.